10/577410 1AP20 Ret'd PCT/PTO: 26 APR 2006

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of John Joseph PARTRIDGE

International Application No.: PCT/US2004/034755

International Filing Date: October 21, 2004

For: Enzyme-Catalyzed Dynamic Kinetic Resolution Process for Preparing (+)-(2S, 3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol and Salts and Solvates Thereof

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

	[X]	Copies of the references are enclosed							
	[]	Copies of the references were submitted in parent application Serial No							
	(37 CFR 1.98(d))								
	[X] A copy of the International Search Report which issued on International Application No.								
	PCT/US2004/034755 is submitted herewith. All of the publications cited in the								
		International Search Report are listed on the attached form PTO-1449 and Applicants							
		understand that copies have been supplied to the U.S. Patent Office by the International Bureau.							
A.	A. [X] The Information Disclosure Statement submitted herewith is being filed months of the filing date of the above application or date of entry into the statement submitted herewith is being filed months.								
		of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).							
	OR								
		The Information Disclosure Statement submitted herewith is being filed before the							
	mailing of a first office action after the filing of a Request For Continued								
		Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).							
В.	[]	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:  (1) a final action under § 1.113 or  (2) a notice of allowance under § 1.311, whichever occurs first.							
Dat I he Off Ale	e of I ereby ice to xand	Mail Label No.: EV332131045US  Mailing: Quil 26, 2006  certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Addressee" service under 37 CFR 1.10 in an envelope addressed to "Commissioner for Patents, P. O. Box 1450, ria, VA 22313-1450 on the date shown above.							
Pat	ty ₩	flson /							

## 10/577410 IAP20 Rec'd PCT/FTO 26 APR 2006

## Atty. Docket No. PR60552USW

	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.						
	[]	Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).						
C.	[]	The Information Disclosure Statement transmitted herewith is being filed <b>after</b> a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.						
	In acco	ordance with the requirements of 37 CFR 1.97(d):						
	[ ]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]						
	[ ]	Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and						
	[ ]	The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.						
		charge any required fees to Deposit Account No.07-1392. cate copy of this paper is attached.						
		Respectfully Submitted,						

Bonnie L. Deppenbrock
Attorney of Record

Registration No. 28,209

Date: <u>20 April 2006</u> Customer No. 23347

Customer No. **2**3347 GlaxoSmithKline

Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-1577 Facsimile: (919) 483-7988

FORM PTO	-1449				INT'L FILING NO. PCT/US2004/034755							
INFORMAT	TION I	DISCLOSURE ST.	ATEMENT		INT'L FILING DATE		October :	October 21, 2004				
					APPLICANT		Partridge	Partridge -				
					GROUP							
					EXAMINER		1966 G	77 410				
					ATTORNEY DO	OCKĚŤ NO.	PR60552	USw				
U.S. PATENT DOCUMENTS												
Examiner Initials		Patent Number	Issue Date		Name	Class	Subclass	Filing Date If Appropriate				
	1.	6,274,579	8/14/2001	Morgan et	al.							
-	2.	6,323,368	11/27/2001	Evans Graham		1						
	3.	6,337,328	1/8/2002	Fang et al.			· · · · · · · · · · · · · · · · · · ·	, , , , , , , , , , , , , , , , , , , ,				
	4.	6,342,496	1/29/2002	Jerussi et a								
	5.	6,391,875	5/21/2002	Morgan et	al.							
_	6.	6,734,213	5/11/2004	Partridge	·-							
	7.	6,855,820	2/15/2005	Broom et	al.			~				
-	8.	2002/052340	5/2/2002	Jerussi et a								
	9.	2002/052341	5/2/2002	Fang et al.								
	<i>J</i> .	2002/032341			DOCUMENTS	<u></u>						
		Document	Publication	NIAILNI	DOCUMENTS			Translation				
		Number	Date	•	Country	Class	Subclass	Yes   No				
	10.	WO 01/62257	8/30/2001	PCT	Journey .	Cinso	<u> </u>					
	10.	WO 01/02237	0/30/2001	101								
<del></del>							·					
		·										
				<del></del>								
			· · · · · · · · · · · · · · · · · · ·									
								,				
		OTHER DOCUM	IENTS (Includia	ag Author	Title Iournal Day	to Page Numi	how Eta )					
	111							ru in the				
11. PARTRIDGE et al., "Enantioselective Synthesis: The Optimum Process" in Process Cher												
Pharmaceutical Industry (Gadamasetti K.G., Ed.) Marcel Dekker, New York, NY 1999, pp. 3  12. REIDER et al., Crystallization-Induced Asymmetric Transformation: Stereospecific Synthes												
12. REIDER et al., Crystallization-Induced Asymmetric Transformation: Stereospecific Synthesis Peripheral CCK Antagonist, J. Org. Chem. 52:955-957 (1987).								as of a fotont				
	13.					ne Derivative v	vith Sodium I	Borohydride-(S)-				
	13. YAMADA et al., Asymmetric Reduction of a 1.5-Benzothiazepine Derivative with Sodium Borohydride-(S)-α-Amino Acids: An Efficient Synthesis of a Key Intermediate of Diltiazem, J. Org. Chem. 61:8586-8590 (1996).											
	14.				rahedron 59(42):82							
	15.				is of cis-3, 5-Diace	toxycyclopent	ene: 1R, 4S-(	+)-4-Hydroxy-2-				
		cyclopentenyl Ac	etate, Org. Synth	Coll. IX:4	87-493 (1998).							
	16.				mmetric Transform		tantiomers, R	acemates and				
	Resolutions, Krieger Publ., Malabar, FL 1991, Chpt. 6, pp. 369-377.											
EXAMINER DATE CONSIDERED												
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through												
citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.												